Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pediatric Endocrinology

Confirming the Diagnosis: Tests and Scans

At a Glance

Doctors confirm pituitary gigantism by interpreting IGF-1 against pediatric age, sex, and puberty ranges, then checking whether growth hormone suppresses after glucose. MRI locates a pituitary tumor, while hormone testing and a bone-age X-ray assess gland function and remaining growth potential.

Diagnosing pituitary gigantism is a careful process of “proving” that the body is making too much growth hormone and finding exactly where that hormone is coming from. Because children’s bodies are constantly changing, your medical team must use specialized tools and reference ranges designed specifically for pediatric patients [1][2].

Step 1: The IGF-1 Screening

The first step is usually a blood test for Insulin-like Growth Factor-1 (IGF-1). Growth hormone (GH) levels fluctuate throughout the day, but IGF-1 remains relatively stable, making it a better “snapshot” of overall hormone activity [3][4].

  • Age and Sex Matters: It is critical to know that children naturally have much higher IGF-1 levels than adults, especially during the “growth spurts” of puberty [1][5]. Also, IGF-1 can be affected by nutrition, thyroid health, and liver or kidney issues.
  • Precise Comparison: Your child’s results must be compared against pediatric-specific reference ranges that account for their exact age, sex, and pubertal stage [1][6]. An “elevated” result in an adult might be perfectly normal for a 13-year-old, so experts look for levels that are significantly above the upper limit for your child’s specific peer group [6][4].

Step 2: The “Sugar Test” (OGTT)

If the IGF-1 is high, doctors may perform an Oral Glucose Tolerance Test (OGTT) to help confirm the diagnosis [6][7].

In a healthy body, drinking a high-sugar (glucose) drink tells the pituitary gland to stop making growth hormone. In a child with gigantism, the GH level fails to drop (suppress) adequately [7][8].

  • Interpreting the Test: The exact cutoff for “failure to suppress” depends on the assay, laboratory calibration, and clinical context [9][10][8]. Specialists interpret the lowest GH level alongside adjusted IGF-1 results, rather than relying on a single universal number. The test may be interpreted differently for patients with diabetes.
  • What to Expect: The test requires fasting. Over about two hours, multiple blood draws track GH and sugar levels after the drink is consumed.

Step 3: Mapping the Tumor (MRI)

Once the hormones confirm the problem, a pituitary-protocol MRI is used to locate the tumor. This high-resolution scan focuses on the sella turcica, the bony pocket where the pituitary sits [11][12].

  • What to Expect: An MRI requires staying perfectly still, often with IV contrast dye. Younger children may require sedation or anesthesia.
    Radiologists look for several key details:
  • Size: Most tumors in children are macroadenomas, meaning they are 10 millimeters (1 cm) or larger [13][14].
  • The Optic Chiasm: This is the spot where the optic nerves (vision) cross directly above the pituitary. The MRI shows if the tumor is pressing on this structure, which can cause vision loss [15][14]. This scan does not replace a formal visual-field exam by an eye specialist.
  • The Cavernous Sinus: These are channels on either side of the pituitary that hold major blood vessels and nerves. If the tumor “invades” these areas, it can make surgical removal more complex [16][17].

Step 4: The Full Hormone Panel

Because the pituitary gland is the “master gland,” a large tumor can physically compress the healthy parts of the gland. This can lead to hypopituitarism, where the body doesn’t make enough of other vital hormones [2][18]. Your doctor will test for:

  • ACTH/Cortisol: Vital for energy and the “stress response.”
  • TSH/Thyroid Hormone: Controls metabolism.
  • Prolactin: This may be elevated if the tumor co-secretes it or presses on the pituitary stalk [19].
  • LH/FSH & Sex Steroids: The hormones that signal the start of puberty.

Step 5: Bone Age X-ray

Finally, an X-ray of the hand and wrist may be used to determine bone age. This helps doctors see if the epiphyses (growth plates) are still open or if they are beginning to fuse [20]. Bone age may be advanced, normal, or delayed depending on nutrition and other hormones. Knowing how much “growth potential” is left helps the team decide how to treat the condition [21].

Common questions in this guide

What tests are used to diagnose pituitary gigantism in a child?
Doctors usually begin with an IGF-1 blood test, which gives a steadier picture of growth hormone activity than a single growth hormone measurement. If IGF-1 is high for the child’s age, sex, and pubertal stage, an oral glucose tolerance test may be used to see whether growth hormone falls after glucose. MRI, a broader hormone panel, and sometimes a bone-age X-ray help complete the evaluation.
Why must IGF-1 results be interpreted using pediatric ranges?
Children normally have higher IGF-1 levels than adults, and levels also change with age, sex, and puberty. Nutrition and thyroid, liver, or kidney problems can affect the result, so doctors compare it with a pediatric reference range rather than an adult cutoff. A high result is meaningful only in the child’s clinical context.
What happens during the glucose suppression test for pituitary gigantism?
The child fasts, drinks a glucose solution, and has several blood samples taken over about two hours. In a healthy response, the glucose drink lowers growth hormone; in pituitary gigantism, growth hormone may not fall enough. The laboratory method and the child’s medical context affect the cutoff doctors use.
What can an MRI show when a child has suspected pituitary gigantism?
A pituitary-focused MRI can show the size and location of a tumor and whether it touches the optic chiasm, the area where the vision nerves cross, or extends into nearby spaces called the cavernous sinuses. These findings can affect the surgical plan, but an MRI does not replace a formal visual-field test by an eye specialist. Younger children may need IV contrast, sedation, or anesthesia to remain still.
Why are other hormone tests and a bone-age X-ray needed?
A large pituitary tumor can press on healthy pituitary tissue, lowering hormones such as ACTH, thyroid-stimulating hormone, or puberty-related hormones. A hand and wrist X-ray estimates bone age and shows whether the growth plates are still open, which helps doctors assess remaining growth potential. Results help the team plan care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How were the IGF-1 results adjusted for exact age, sex, and stage of puberty?
  2. 2.Does the lab that performed the OGTT use a specific GH suppression cutoff, and how does clinical context affect that interpretation?
  3. 3.Does the MRI show any contact with the optic chiasm or invasion of the cavernous sinus, and how does that affect the surgical plan?
  4. 4.Were any other pituitary hormones, like ACTH or TSH, found to be low due to the tumor's size?
  5. 5.What does the bone age tell us about how much more height might be gained?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Establishment of IGF-1 and IGFBP-3 continuous reference percentiles from data of healthy children using three kinds of immunoassay systems.

    Jo Y, Song K, Heo SJ, et al.

    Heliyon 2024; (10(19)):e38245 doi:10.1016/j.heliyon.2024.e38245.

    PMID: 39403490
  2. 2

    Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.

    Korbonits M, Blair JC, Boguslawska A, et al.

    Nature reviews. Endocrinology 2024; (20(5)):290-309 doi:10.1038/s41574-023-00949-7.

    PMID: 38336898
  3. 3

    Gigantism.

    Donato S, Regala C, Marques P

    Vitamins and hormones 2026; (131()):195-234 doi:10.1016/bs.vh.2025.10.005.

    PMID: 41912294
  4. 4

    Consensus on criteria for acromegaly diagnosis and remission.

    Giustina A, Biermasz N, Casanueva FF, et al.

    Pituitary 2024; (27(1)):7-22 doi:10.1007/s11102-023-01360-1.

    PMID: 37923946
  5. 5

    Pediatric Continuous Reference Intervals of Serum Insulin-like Growth Factor 1 Levels in a Healthy Chinese Children Population - Based on PRINCE Study.

    Cao B, Peng Y, Song W, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(7)):696-702 doi:10.1016/j.eprac.2022.04.004.

    PMID: 35430364
  6. 6

    Reversible Growth Hormone Excess in Two Girls with Neurofibromatosis Type 1 and Optic Pathway Glioma.

    Bruzzi P, Sani I, Albanese A

    Hormone research in paediatrics 2015; (84(6)):414-22 doi:10.1159/000440956.

    PMID: 26488470
  7. 7

    Acromegaly with initial negative oral glucose tolerance test: a case report.

    Tsai WH, Chien MN, Dai SH, Chan YK

    Journal of medical case reports 2023; (17(1)):333 doi:10.1186/s13256-023-04064-z.

    PMID: 37543629
  8. 8

    Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions.

    Hage M, Kamenický P, Chanson P

    Neuroendocrinology 2019; (108(3)):244-255 doi:10.1159/000497214.

    PMID: 30685760
  9. 9

    Successful treatment of pituitary gigantism.

    Cunha C, Saraiva C, Canas Marques C, Duarte JS

    BMJ case reports 2021; (14(12)) doi:10.1136/bcr-2021-247989.

    PMID: 34972788
  10. 10

    Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

    Dobri G, Niwattisaiwong S, Bena JF, et al.

    Endocrine 2019; (64(1)):139-146 doi:10.1007/s12020-018-1805-z.

    PMID: 30415402
  11. 11

    Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis.

    Del Corso LM, Mesa Junior CO, Andrade VFC, et al.

    Pituitary 2024; (27(5)):537-544 doi:10.1007/s11102-024-01432-w.

    PMID: 39088137
  12. 12

    Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.

    Daskareh M, Abbasi F, Emamzadeh N, et al.

    Diagnostics (Basel, Switzerland) 2026; (16(16)) doi:10.3390/diagnostics16162582.

    PMID: 42650985
  13. 13

    Pituitary-Targeted Dynamic Contrast-Enhanced Multisection CT for Detecting MR Imaging-Occult Functional Pituitary Microadenoma.

    Kinoshita M, Tanaka H, Arita H, et al.

    AJNR. American journal of neuroradiology 2015; (36(5)):904-8 doi:10.3174/ajnr.A4220.

    PMID: 25593201
  14. 14

    Inoperable Giant Growth Hormone-secreting Pituitary Adenoma: Radiological Aspects, Clinical Management and Pregnancy Outcome.

    Dicuonzo F, Purciariello S, De Marco A, et al.

    Endocrine, metabolic & immune disorders drug targets 2019; (19(2)):214-220 doi:10.2174/1871530318666180807160712.

    PMID: 30088454
  15. 15

    The influence of pituitary adenoma size on vision and visual outcomes after trans-sphenoidal adenectomy: a report of 78 cases.

    Ho RW, Huang HM, Ho JT

    Journal of Korean Neurosurgical Society 2015; (57(1)):23-31 doi:10.3340/jkns.2015.57.1.23.

    PMID: 25674340
  16. 16

    Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis.

    Briceno V, Zaidi HA, Doucette JA, et al.

    Neurological research 2017; (39(5)):387-398 doi:10.1080/01616412.2017.1296653.

    PMID: 28301972
  17. 17

    The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase IIα.

    Kwinta BM, Wilk A, Trofimiuk-Muldner M, et al.

    Endokrynologia Polska 2018; (69(5)):530-535 doi:10.5603/EP.a2018.0050.

    PMID: 30074233
  18. 18

    Approach to the Patient: A Case With an Unusual Cause of Hypopituitarism.

    Das L, Dutta P

    The Journal of clinical endocrinology and metabolism 2023; (108(6)):1488-1504 doi:10.1210/clinem/dgac747.

    PMID: 36573291
  19. 19

    Mixed gangliocytoma-pituitary adenoma containing GH and GHRH co-secreting adenoma cells.

    Teramoto S, Tange Y, Ishii H, et al.

    Endocrinology, diabetes & metabolism case reports 2019; (2019()).

    PMID: 31581122
  20. 20

    Genetics of gigantism and acromegaly.

    Hannah-Shmouni F, Trivellin G, Stratakis CA

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2016; (30-31()):37-41 doi:10.1016/j.ghir.2016.08.002.

    PMID: 27657986
  21. 21

    Challenges in the Management of a 7-Year-Old Child with Thyrotropin-Secreting Pituitary Adenoma and the Review of the Literature.

    Kirkgoz T, Abali S, Seker A, et al.

    Hormone research in paediatrics 2023; (96(5)):527-537 doi:10.1159/000529070.

    PMID: 36630941

This page explains testing for suspected pituitary gigantism in children for informational purposes only and does not constitute medical advice. Your child’s endocrinology team should interpret the results and recommend next steps.

Get notified when new evidence is published on Pituitary gigantism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.